| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
12,810 |
8,012 |
$867K |
| 99215 |
Prolong outpt/office vis |
1,190 |
806 |
$107K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
2,290 |
1,583 |
$89K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
2,567 |
1,773 |
$62K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
571 |
453 |
$59K |
| 99396 |
Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years |
246 |
171 |
$18K |
| 87428 |
|
357 |
332 |
$11K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
807 |
335 |
$10K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
902 |
607 |
$9K |
| 99395 |
Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years |
77 |
71 |
$7K |
| 36415 |
Collection of venous blood by venipuncture |
1,779 |
1,251 |
$7K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
592 |
470 |
$7K |
| 90674 |
|
414 |
285 |
$6K |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
167 |
118 |
$3K |
| 80305 |
|
348 |
224 |
$3K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
341 |
237 |
$2K |
| 81002 |
|
399 |
259 |
$796.58 |
| 81025 |
|
42 |
29 |
$233.82 |
| 90686 |
|
20 |
17 |
$212.02 |
| J2930 |
Injection, methylprednisolone sodium succinate, up to 125 mg |
45 |
27 |
$154.83 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
36 |
29 |
$65.49 |
| 99072 |
|
848 |
586 |
$0.00 |